Dr. Landgren Discusses MRD Detection for Multiple Myeloma
C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.
C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma.
Several studies show that those who are MRD-negative often have a better PFS and OS compared with those who are MRD-positive, Landgren explains.
Similar to other disease types where MRD detection is used, Landgren says there is a gradient of sensitivity for these assays. For patients who are MRD-negative, less disease is detected.
<<<
